Clinical transplantation and research · 2026
Sirolimus-based immunosuppression and reported rejection or death in heart transplant recipients using the U.S. Food and Drug Administration Adverse Event Reporting System.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ogura Toru, Shiraishi Chihiro, Urawa Aiko
Аннотация
BACKGROUND: Sirolimus, although not approved for heart transplant recipients (HTRs), is frequently prescribed off-label for mitigating calcineurin inhibitor-related toxicity and promoting graft survival. However, its adverse event profile and real-world outcome associations within specific immunosuppressive combinations remain unclear.
METHODS: This retrospective pharmacovigilance study utilized data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). To minimize confounding by concomitant medication, paired comparisons were restricted to regimens differing only by sirolimus use. Reporting odds ratios (RORs) and adjusted RORs (aRORs), controlling for demographic and geographic variables, were calculated for the composite outcome of transplant rejection or death. Each sirolimus-containing regimen was compared with its corresponding nonsirolimus reference.
RESULTS: The sirolimus plus tacrolimus regimen showed lower disproportional reporting of transplant rejection or death than the tacrolimus regimen (ROR, 0.532 [95% CI, 0.284-0.994], P=0.048; aROR, 0.419 [95% CI, 0.218-0.804], P=0.009). In other tacrolimus-based regimens (tacrolimus plus mycophenolic acid, tacrolimus plus prednisone, and tacrolimus plus mycophenolic acid plus prednisone), sirolimus addition consistently showed RORs and aRORs <1.000, indicating a similar but nonsignificant trend toward lower reporting of transplant rejection or death.
CONCLUSIONS: This FAERS-based analysis suggested an association between sirolimus-containing regimens and lower disproportional reporting of transplant rejection or death among HTRs. These findings should be interpreted as hypothesis-generating, as spontaneous reporting data are susceptible to confounding and cannot establish causality. Prospective studies with detailed clinical data are needed to determine whether this association persists after adequate confounding control.
METHODS: This retrospective pharmacovigilance study utilized data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). To minimize confounding by concomitant medication, paired comparisons were restricted to regimens differing only by sirolimus use. Reporting odds ratios (RORs) and adjusted RORs (aRORs), controlling for demographic and geographic variables, were calculated for the composite outcome of transplant rejection or death. Each sirolimus-containing regimen was compared with its corresponding nonsirolimus reference.
RESULTS: The sirolimus plus tacrolimus regimen showed lower disproportional reporting of transplant rejection or death than the tacrolimus regimen (ROR, 0.532 [95% CI, 0.284-0.994], P=0.048; aROR, 0.419 [95% CI, 0.218-0.804], P=0.009). In other tacrolimus-based regimens (tacrolimus plus mycophenolic acid, tacrolimus plus prednisone, and tacrolimus plus mycophenolic acid plus prednisone), sirolimus addition consistently showed RORs and aRORs <1.000, indicating a similar but nonsignificant trend toward lower reporting of transplant rejection or death.
CONCLUSIONS: This FAERS-based analysis suggested an association between sirolimus-containing regimens and lower disproportional reporting of transplant rejection or death among HTRs. These findings should be interpreted as hypothesis-generating, as spontaneous reporting data are susceptible to confounding and cannot establish causality. Prospective studies with detailed clinical data are needed to determine whether this association persists after adequate confounding control.